ADMA Biologics vs Roivant Sciences

Add, change or remove companies; up to four.

KIRA’s take AI analyst

I put ADMA Biologics and Roivant Sciences side by side, using each one’s latest annual report. Here is what stands out:

ADMA Biologics is the larger business, with $510M of revenue in fiscal 2025 against $8.3M for Roivant Sciences, about 61 times as much.
ADMA Biologics grew revenue faster (19.6%, against −71.6%).
ADMA Biologics kept more of each dollar of sales as operating profit (37.5% operating margin, against −6,235.7%).
ADMA Biologics turned more of its sales into free cash flow (5.5% FCF margin, against −9,183.5%).
ADMA Biologics earned a higher return on the capital invested in it (39.5%, against −62.6%).

Who comes out ahead

Of the 9 measures where higher (or lower) is clearly better, how many each company leads.

ADMA Biologics

ADMA

8/9

Revenue growth5-year growthOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-score

Roivant Sciences

ROIV

1/9

Share count change

Side by side

Best in the row

Latest fiscal year	ADMA FY25	ROIV FY25
Size
Market cap	$2.5B	$26.3B
Revenue	$510M	$8.3M
Free cash flow	$27.8M	−$759M
Net income	$147M	−$300M
Growth
Revenue growth	19.6%	−71.6%
5-year growth	64.6%	−19.0%
Share count change	0.6%	−4.4%
Profitability
Gross margin	57.4%	—
Operating margin	37.5%	−6,235.7%
Net margin	28.8%	−3,629.2%
FCF margin	5.5%	−9,183.5%
Return on capital	39.5%	−62.6%
Return on equity	35.6%	−6.5%
Balance sheet
Net debt	−$15.5M	−$4.3B
Net debt / EBITDA	−0.1x	—
Dividends and buybacks	$31.9M	$0.0M
Valuation & quality
P/E	15.3x	—
Piotroski F-score	5	1

Ten years

Revenue

FY16

ADMA $10.7M

ROIV —

FY17

ADMA $22.8M

ROIV —

FY18

ADMA $17.0M

ROIV —

FY19

ADMA $29.3M

ROIV —

FY20

ADMA $42.2M

ROIV $23.8M

FY21

ADMA $80.9M

ROIV $55.3M

FY22

ADMA $154M

ROIV $31.5M

FY23

ADMA $258M

ROIV $32.7M

FY24

ADMA $427M

ROIV $29.1M

FY25

ADMA $510M

ROIV $8.3M

FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

ADMA ROIV

Operating margin

FY16

ADMA −162.6%

ROIV —

FY17

ADMA −172.7%

ROIV —

FY18

ADMA −355.0%

ROIV —

FY19

ADMA −141.1%

ROIV —

FY20

ADMA −153.8%

ROIV −4,500.5%

FY21

ADMA −72.1%

ROIV −2,444.8%

FY22

ADMA −25.6%

ROIV −2,875.9%

FY23

ADMA 8.4%

ROIV 13,746.9%

FY24

ADMA 32.6%

ROIV −3,453.3%

FY25

ADMA 37.5%

ROIV −6,235.7%

FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

ADMA ROIV

Free cash flow

FY16

ADMA −$18.3M

ROIV —

FY17

ADMA −$40.0M

ROIV —

FY18

ADMA −$64.8M

ROIV —

FY19

ADMA −$80.0M

ROIV —

FY20

ADMA −$115M

ROIV −$558M

FY21

ADMA −$126M

ROIV −$695M

FY22

ADMA −$73.4M

ROIV −$856M

FY23

ADMA $4.0M

ROIV −$767M

FY24

ADMA $110M

ROIV −$844M

FY25

ADMA $27.8M

ROIV −$759M

FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

ADMA ROIV

Return on capital

FY16

ADMA —

ROIV —

FY17

ADMA —

ROIV —

FY18

ADMA —

ROIV —

FY19

ADMA —

ROIV —

FY20

ADMA −82.2%

ROIV —

FY21

ADMA −29.7%

ROIV —

FY22

ADMA −15.8%

ROIV −286.2%

FY23

ADMA 8.1%

ROIV —

FY24

ADMA 52.2%

ROIV —

FY25

ADMA 39.5%

ROIV −62.6%

FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

ADMA ROIV

Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.